CT-proADM Biomarker for Cardiovascular Risk Stratification
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods lack reliability for accurately diagnosing and stratifying the risk of cardiovascular diseases, cardiac insufficiency, and infections of the lungs and respiratory tract, particularly in terms of severity and clinical decision-making in critical care settings.
Innovation Solution
The use of the CT-proADM (C-terminal fragment of proAdrenomedullin) marker or its partial peptides, determined in patient samples, as part of a marker combination, for in-vitro diagnosis and risk stratification, allowing for quicker and more effective clinical decisions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current diagnostic methods are used, then diagnosis can be performed, but reliability and accuracy for risk stratification are insufficient
Solution Approach 1:
The patent introduces a new diagnostic parameter (CT-proADM marker) to improve both reliability and measurement precision. By measuring C-terminal fragments of proadrenomedullin in patient samples, the method provides a novel biomarker that enables more accurate risk stratification and diagnosis of cardiovascular diseases, cardiac insufficiency, and respiratory infections, directly addressing the insufficiency of current diagnostic parameters
2Measurement precision
If comprehensive marker combinations are used for accurate diagnosis, then diagnostic accuracy improves, but complexity of the diagnostic process increases
Solution Approach 1:
The patent segments the diagnostic approach by introducing a specific, well-defined marker (CT-proADM) that can be measured independently. This segmented approach allows the marker to be used either alone or in combination with other markers, providing diagnostic accuracy without necessarily increasing overall process complexity, as the marker targets specific physiological pathways
3Loss of time
If rapid diagnosis is implemented for quick clinical decisions, then treatment time is reduced, but diagnostic reliability may be compromised
Solution Approach 1:
The CT-proADM marker serves as a preliminary indicator that can be measured early in the diagnostic process. By providing early information about disease presence, severity, and risk stratification, the marker enables quick initial assessments and clinical decisions while maintaining reliability, as the marker reflects underlying physiological processes that cannot be rapidly changed
Data Source
AI summary
The invention relates to a novel diagnostic marker CT-proADM (C-terminal fragment of preproADM, SEQ ID No. 1) for diagnosing and/or stratifying the risk of diseases. Also disclosed is a method for diagnosing and/or stratifying the risk of diseases, particularly cardiovascular diseases, cardiac insufficiency, and infections and/or inflammations of the lungs and respiratory tract. In said method, the CT-proADM (SEQ ID No. 1) marker, or a partial peptide of fragment thereof, or said marker contained in a marker combination (panel, cluster) is determined in a patient who is to be examined. The invention further relates to a diagnostic apparatus as well as a kit for carrying out said method.